|
HAYWARD, CA, September 21, 1999 - Sepragen Corporation (OTC BB: SPGNU, SPGNA, SPGNW) announced the
successful start of the first plant in Europe based on its patented Sepralac® Process.
The plant was commissioned by Carbery Food Ingredients, of Ireland, pursuant to a license
agreement reached between Sepragen and Carbery.
Carberys plant will produce, amongst other ingredients, alpha-lactalbumin and
lactoferrin which are high value ingredients extracted from cheese whey. These ingredients
are being targeted for producing next generation infant formulae that more closely
resemble the protein profile of human breast milk, and as health enhancing additives in
nutraceutical or dietary supplement products. Carbery will also utilize some
innovative whey fractions to enhance its existing Isolac range of sportsfood ingredients.
Said John Holland, Operations Director for Carbery, Carbery Food Ingredients is a
technology leader in the manufacture of whey based ingredients and is a well recognized
supplier to leading infant formulae producers. The manufacture of this new generation of
ingredients will enable us to continue operating at the frontiers of whey technology and
give us the ability to better serve our customers with exciting technical innovations. We
expect our relationship with Sepragen to grow as we position ourselves as a global
supplier of high-end ingredients to both existing and new customers.
Sepragen Corporation develops and markets technology along with equipment and supplies
for process chromatography applications. Sepragen has developed a number of patented
applications that provide large market opportunities in the food and beverage industry,
including debittering citrus juices, extracting isoflavone (plant estrogen) from soy, as
well as extracting proteins from whey. The company holds over 14 issued patents relating
to its core technology.
<
Back
The statements in this release that relate to future events
or performance, statements about growth, future regulatory clearances, levels of sales and
market size and future manufacturing capacity and efficiencies are forward-looking
statements that involve risks and uncertainties, including risks associated with
uncertainties related to the development of markets for and commercial acceptance of the
company's products and services, the availability of components, competitors' product
introductions and other risks identified in the company's SEC filings. Actual results may
differ from those described in these forward-looking statements. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak only as of the
date hereof.
|